Publications by authors named "Kenji Kurazono"
Article Synopsis
- The study aimed to explore the preferences of the Japanese public regarding government policies to manage infectious disease outbreaks.
- A survey, using conjoint analysis with 2,185 respondents, found that accessibility to therapeutic drugs, tests, and vaccines was highly valued, with drug accessibility having the highest estimated monetary value of JPY 10.5 trillion.
- The findings indicated a clear preference for accessibility of medical resources over behavioral or entry restrictions during the ongoing COVID-19 pandemic, although the sample may not fully represent the broader population.
Introduction: During the recent coronavirus disease 2019 (COVID-19) pandemic, preferences for factors associated with vaccines have been evaluated. Three oral antiviral drugs have been approved in Japan for patients with mild-to-moderate I COVID-19 symptoms. Although preferences for the drugs may also depend on various factors, these have not been fully evaluated.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluates the inconvenience costs of influenza antivirals for children in Japan by analyzing parent feedback on different drug characteristics.
- An online survey collected data from parents of 6-11 year olds who had used antivirals, focusing on various drug forms (tablet, capsule, etc.), administration frequency, and costs.
- Results showed that tablets were the preferred option, with other forms incurring higher inconvenience costs, highlighting that single-dose tablets are optimal for minimizing issues during treatment.
Aims: To estimate the cost of antiviral medication guidance and/or support from the perspective of healthcare professionals by administration route (oral or inhalant).
Methods: An online survey (December 2020) was conducted among physicians, pharmacists, and certified care workers. Those aged 20-64 years working in workplaces with experience of prescribing (physicians) or dispensing (pharmacists) antivirals for influenza, or having care service recipients who took antivirals (certified care workers) since October 2018, were selected through screening questions.
Background And Aim: Thrombocytopenia is a frequent hematological condition in chronic liver disease (CLD) patients increasing the risk of bleeding in patients undergoing invasive procedures. Without an alternative, clinical guidelines recommended the use of platelet transfusion (PT) prior to procedure to prevent this bleeding risk. Lusutrombopag (LUSU), an orally active, small-molecule thrombopoietin receptor agonist, was developed as an alternative to PT.
View Article and Find Full Text PDF